科研之友
微信
新浪微博
Facebook
分享链接
摘要
Dimethyl fumarate (DMF) is an immunomodulatory drug used in patients with multiple sclerosis (MS) and psoriasis. Kornberg and colleagues shed new light on DMF activity, demonstrating that it blocks immune cell activation through inhibition of glycolysis via post-transcriptional modification of glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which confirms the pro-inflammatory role of glycolysis and points to potential new targets to treat inflammatory diseases such as MS.
- 出版日期2018-6
